Tamoxifen and breast cancer prevention: what should you tell your patients?
作者信息
Goel V
出版信息
CMAJ. 1998 Jun 16;158(12):1615-7.
Abstract
摘要
相似文献
1
Tamoxifen and breast cancer prevention: what should you tell your patients?他莫昔芬与乳腺癌预防：你该如何告知你的患者？
CMAJ. 1998 Jun 16;158(12):1615-7.
2
How do we interpret the results of the Breast Cancer Prevention trial?我们如何解读乳腺癌预防试验的结果？
CMAJ. 1998 Jun 16;158(12):1613-4.
3
DM effort seeks to improve outcomes through prevention, early detection of breast cancer.
Dis Manag Advis. 2000 Sep;6(9):140-4, 132.
4
5
Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.绝经后女性使用他莫昔芬或雷洛昔芬预防乳腺癌：两种选择的对比——正方与反方观点
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2210-2. doi: 10.1158/1055-9965.EPI-06-1065.
6
Keeping breast cancer at bay. Women at risk are asked to weigh the pros and cons of a prevention pill.预防乳腺癌。有风险的女性被要求权衡一种预防药物的利弊。
US News World Rep. 1999 May 31;126(21):76.
7
Tamoxifen in cancer therapy: minireview.他莫昔芬在癌症治疗中的应用：综述
Neoplasma. 2000;47(1):3-7.
8
The current status of breast cancer chemoprevention: a star is born.乳腺癌化学预防的现状：一颗新星诞生了。
J Surg Oncol. 2007 Jan 1;95(1):4-5. doi: 10.1002/jso.20658.
9
Final results from the NSABP Breast Cancer Prevention Trial.国家外科辅助乳腺和肠道项目（NSABP）乳腺癌预防试验的最终结果。
Oncology (Williston Park). 2005 Dec;19(14):1800.
10
Tamoxifen: an enduring star.他莫昔芬：一颗永恒的明星。
J Natl Cancer Inst. 2007 Feb 21;99(4):258-60. doi: 10.1093/jnci/djk072.
引用本文的文献
1
Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.他莫昔芬用于乳腺癌化学预防：在对乳腺肿块进行评估后，高危女性对其的接受度较低。
Ann Fam Med. 2005 May-Jun;3(3):242-7. doi: 10.1370/afm.284.
2
Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.遗传性乳腺癌。BRCA1和BRCA2携带者的识别与管理。
Can Fam Physician. 1999 Jan;45:114-24.
本文引用的文献
1
Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue.他莫昔芬用于预防乳腺癌。重要问题仍未得到解答，现有试验应继续进行。
BMJ. 1998 Apr 18;316(7139):1181-2. doi: 10.1136/bmj.316.7139.1181.
2
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.BRCA1基因突变对阿什肯纳兹犹太女性乳腺癌核分级及雌激素受体状态的影响。
Cancer. 1997 Aug 1;80(3):435-41. doi: 10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y.
3
Epidemiology and prevention of breast cancer.乳腺癌的流行病学与预防
Annu Rev Public Health. 1996;17:47-67. doi: 10.1146/annurev.pu.17.050196.000403.
4
Alternate antiestrogens and approaches to the prevention of breast cancer.替代抗雌激素药物及乳腺癌预防方法
J Cell Biochem Suppl. 1995;22:51-7. doi: 10.1002/jcb.240590808.
5
Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making.首要的是不伤害？治疗决策中药物毒性风险的评估。
Clin Pharmacol Ther. 1993 Mar;53(3):285-91. doi: 10.1038/clpt.1993.23.
6
Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial.他莫昔芬用于乳腺癌的一级预防：概念与试验的综述及评论
Epidemiol Rev. 1993;15(1):233-43. doi: 10.1093/oxfordjournals.epirev.a036110.
7
The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs.
Am J Med. 1995 Aug;99(2):180-9. doi: 10.1016/s0002-9343(99)80138-7.
8
Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.他莫昔芬：乳腺癌治疗与预防过程中的毒性及耐药性
Annu Rev Pharmacol Toxicol. 1995;35:195-211. doi: 10.1146/annurev.pa.35.040195.001211.
9
Antiestrogens as chemopreventive agents in breast cancer: promise and issues in evaluation.抗雌激素作为乳腺癌化学预防剂：前景与评估中的问题
Prev Med. 1989 Sep;18(5):661-71. doi: 10.1016/0091-7435(89)90037-6.
10
NIH fends off critics of tamoxifen study.
Science. 1992 Oct 30;258(5083):734. doi: 10.1126/science.1439776.
Zotero 插件